Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.

Nie Z, Shi L, Lai C, Severin C, Xu J, Del Rosario JR, Stansfield RK, Cho RW, Kanouni T, Veal JM, Stafford JA, Chen YK.

Bioorg Med Chem Lett. 2019 Jan 1;29(1):103-106. doi: 10.1016/j.bmcl.2018.11.001. Epub 2018 Nov 3.

PMID:
30409536
2.

Acute sialadenitis associated with 2017-2018 influenza A infection: A case series.

Stafford JA, Moore CA, Mark JR.

Laryngoscope. 2018 Nov;128(11):2500-2502. doi: 10.1002/lary.27202. Epub 2018 Apr 15.

PMID:
29658106
3.

Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.

Bennett MJ, Wu Y, Boloor A, Matuszkiewicz J, O'Connell SM, Shi L, Stansfield RK, Del Rosario JR, Veal JM, Hosfield DJ, Xu J, Kaldor SW, Stafford JA, Betancort JM.

Bioorg Med Chem Lett. 2018 Jun 1;28(10):1811-1816. doi: 10.1016/j.bmcl.2018.04.016. Epub 2018 Apr 10.

PMID:
29657099
4.

Structure-based design and discovery of potent and selective KDM5 inhibitors.

Nie Z, Shi L, Lai C, O'Connell SM, Xu J, Stansfield RK, Hosfield DJ, Veal JM, Stafford JA.

Bioorg Med Chem Lett. 2018 May 15;28(9):1490-1494. doi: 10.1016/j.bmcl.2018.03.083. Epub 2018 Mar 30.

PMID:
29627262
5.

Dizziness Handicap Inventory Score Is Highly Correlated With Markers of Gait Disturbance.

Zanotto D, Mamuyac EM, Chambers AR, Nemer JS, Stafford JA, Agrawal SK, Lalwani AK.

Otol Neurotol. 2017 Dec;38(10):1490-1499. doi: 10.1097/MAO.0000000000001586.

PMID:
28984811
6.

KDM4 Inhibition Targets Breast Cancer Stem-like Cells.

Metzger E, Stepputtis SS, Strietz J, Preca BT, Urban S, Willmann D, Allen A, Zenk F, Iovino N, Bronsert P, Proske A, Follo M, Boerries M, Stickeler E, Xu J, Wallace MB, Stafford JA, Kanouni T, Maurer J, Schüle R.

Cancer Res. 2017 Nov 1;77(21):5900-5912. doi: 10.1158/0008-5472.CAN-17-1754. Epub 2017 Sep 7.

7.

Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models.

Chen YK, Bonaldi T, Cuomo A, Del Rosario JR, Hosfield DJ, Kanouni T, Kao SC, Lai C, Lobo NA, Matuszkiewicz J, McGeehan A, O'Connell SM, Shi L, Stafford JA, Stansfield RK, Veal JM, Weiss MS, Yuen NY, Wallace MB.

ACS Med Chem Lett. 2017 Jul 27;8(8):869-874. doi: 10.1021/acsmedchemlett.7b00220. eCollection 2017 Aug 10.

8.

Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial.

Cowper PA, Sheng S, Lopes RD, Anstrom KJ, Stafford JA, Davidson-Ray L, Al-Khatib SM, Ansell J, Dorian P, Husted S, McMurray JJV, Steg PG, Alexander JH, Wallentin L, Granger CB, Mark DB.

JAMA Cardiol. 2017 May 1;2(5):525-534. doi: 10.1001/jamacardio.2017.0065.

9.

When is it safe to operate following myocardial infarction?

Stafford JA, Drusin RE, Lalwani AK.

Laryngoscope. 2016 Feb;126(2):299-301. doi: 10.1002/lary.25597. Epub 2015 Sep 7. Review. No abstract available.

PMID:
26344928
10.

Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke.

Navar-Boggan AM, Rymer JA, Piccini JP, Shatila W, Ring L, Stafford JA, Al-Khatib SM, Peterson ED.

Am Heart J. 2015 Jan;169(1):39-44.e2. doi: 10.1016/j.ahj.2014.09.014. Epub 2014 Oct 22.

PMID:
25497246
11.

Variability in performance measures for assessment of hypertension control.

Navar-Boggan AM, Shah BR, Boggan JC, Stafford JA, Peterson ED.

Am Heart J. 2013 May;165(5):823-7. doi: 10.1016/j.ahj.2013.01.003. Epub 2013 Feb 5.

PMID:
23622921
12.

Structure-based design of pyridopyrimidinediones as dipeptidyl peptidase IV inhibitors.

Lam B, Zhang Z, Stafford JA, Skene RJ, Shi L, Gwaltney SL 2nd.

Bioorg Med Chem Lett. 2012 Nov 1;22(21):6628-31. doi: 10.1016/j.bmcl.2012.08.110. Epub 2012 Sep 7.

PMID:
23025999
13.

Hypertension control among patients followed by cardiologists.

Navar-Boggan AM, Boggan JC, Stafford JA, Muhlbaier LH, McCarver C, Peterson ED.

Circ Cardiovasc Qual Outcomes. 2012 May;5(3):352-7. doi: 10.1161/CIRCOUTCOMES.111.963488. Epub 2012 May 1.

PMID:
22550131
14.

Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial.

Calvert SB, Kramer JM, Anstrom KJ, Kaltenbach LA, Stafford JA, Allen LaPointe NM.

Am Heart J. 2012 Apr;163(4):657-65.e1. doi: 10.1016/j.ahj.2012.01.019.

PMID:
22520532
15.

Association between patient beliefs and medication adherence following hospitalization for acute coronary syndrome.

Allen LaPointe NM, Ou FS, Calvert SB, Melloni C, Stafford JA, Harding T, Peterson ED, Alexander KP.

Am Heart J. 2011 May;161(5):855-63. doi: 10.1016/j.ahj.2011.02.009.

PMID:
21570514
16.

Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.

Zhang Z, Wallace MB, Feng J, Stafford JA, Skene RJ, Shi L, Lee B, Aertgeerts K, Jennings A, Xu R, Kassel DB, Kaldor SW, Navre M, Webb DR, Gwaltney SL.

J Med Chem. 2011 Jan 27;54(2):510-24. doi: 10.1021/jm101016w. Epub 2010 Dec 27.

PMID:
21186796
17.

The application of (Z)-3-aryl-3-haloenoic acids to the synthesis of (Z)-5-benzylidene-4-arylpyrrol-2(5H)-ones.

Gupton JT, Telang N, Banner EJ, Kluball EJ, Hall KE, Finzel KL, Jia X, Bates SR, Welden RS, Giglio BC, Eaton JE, Barelli PJ, Firich LT, Stafford JA, Coppock MB, Worrall EF, Kanters RP, Keertikar K, Osterman R.

Tetrahedron. 2010 Nov 20;66(47):9113-9122.

18.

Changes in beliefs about medications during long-term care for ischemic heart disease.

Allen LaPointe NM, Ou FS, Calvert SB, Melloni C, Stafford JA, Harding T, Alexander KP, Peterson ED.

Am Heart J. 2010 Apr;159(4):561-9. doi: 10.1016/j.ahj.2009.12.025.

PMID:
20362713
19.

Use of beta-blockers in patients with an implantable cardioverter defibrillator.

LaPointe NM, Stafford JA, Pappas PA, Al-Khatib SM, Anstrom KJ.

Ann Pharmacother. 2009 Jul;43(7):1189-96. doi: 10.1345/aph.1M140. Epub 2009 Jun 30.

PMID:
19567655
20.

Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease.

Allen LaPointe NM, Zhou Y, Stafford JA, Hernandez AF, Kramer JM, Anstrom KJ.

Am J Cardiol. 2009 Jun 1;103(11):1518-24. doi: 10.1016/j.amjcard.2009.01.363. Epub 2009 Apr 8.

PMID:
19463509
21.

Do income level and race influence survival in patients receiving hemodialysis?

Eisenstein EL, Sun JL, Anstrom KJ, Stafford JA, Szczech LA, Muhlbaier LH, Mark DB.

Am J Med. 2009 Feb;122(2):170-80. doi: 10.1016/j.amjmed.2008.08.025.

PMID:
19185093
22.

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.

Harris PA, Boloor A, Cheung M, Kumar R, Crosby RM, Davis-Ward RG, Epperly AH, Hinkle KW, Hunter RN 3rd, Johnson JH, Knick VB, Laudeman CP, Luttrell DK, Mook RA, Nolte RT, Rudolph SK, Szewczyk JR, Truesdale AT, Veal JM, Wang L, Stafford JA.

J Med Chem. 2008 Aug 14;51(15):4632-40. doi: 10.1021/jm800566m. Epub 2008 Jul 12.

PMID:
18620382
23.

Re-evaluating the volume-outcome relationship in hemodialysis patients.

Eisenstein EL, Sun JL, Anstrom KJ, Stafford JA, Szczech LA, Muhlbaier LH, Mark DB.

Health Policy. 2008 Dec;88(2-3):317-25. doi: 10.1016/j.healthpol.2008.03.017. Epub 2008 May 27.

PMID:
18502534
24.

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.

Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK, Cheung M.

Mol Cancer Ther. 2007 Jul;6(7):2012-21.

25.

CNS 7056: a novel ultra-short-acting Benzodiazepine.

Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, Wiard RP, Feldman PL, Collins H, Waszczak BL, Tilbrook GS.

Anesthesiology. 2007 Jul;107(1):60-6.

PMID:
17585216
26.

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.

Feng J, Zhang Z, Wallace MB, Stafford JA, Kaldor SW, Kassel DB, Navre M, Shi L, Skene RJ, Asakawa T, Takeuchi K, Xu R, Webb DR, Gwaltney SL 2nd.

J Med Chem. 2007 May 17;50(10):2297-300. Epub 2007 Apr 19. Erratum in: J Med Chem. 2008 Jul 24;51(14):4357.

PMID:
17441705
27.

Is early too early? Effect of shorter stays after bypass surgery.

Cowper PA, DeLong ER, Hannan EL, Muhlbaier LH, Lytle BL, Jones RH, Holman WL, Pokorny JJ, Stafford JA, Mark DB, Peterson ED.

Ann Thorac Surg. 2007 Jan;83(1):100-7.

PMID:
17184638
28.

Trends in postoperative length of stay after bypass surgery.

Cowper PA, DeLong ER, Hannan EL, Muhlbaier LH, Lytle BL, Jones RH, Holman WL, Pokorny JJ, Stafford JA, Mark DB, Peterson ED.

Am Heart J. 2006 Dec;152(6):1194-200.

PMID:
17161075
29.

Use of surgery in patients with native valve infective endocarditis: results from the International Collaboration on Endocarditis Merged Database.

Cabell CH, Abrutyn E, Fowler VG Jr, Hoen B, Miro JM, Corey GR, Olaison L, Pappas P, Anstrom KJ, Stafford JA, Eykyn S, Habib G, Mestres CA, Wang A; International Collaboration on Endocarditis Merged Database (ICE-MD) Study Group Investigators.

Am Heart J. 2005 Nov;150(5):1092-8.

PMID:
16291004
30.

The use and effect of surgical therapy for prosthetic valve infective endocarditis: a propensity analysis of a multicenter, international cohort.

Wang A, Pappas P, Anstrom KJ, Abrutyn E, Fowler VG Jr, Hoen B, Miro JM, Corey GR, Olaison L, Stafford JA, Mestres CA, Cabell CH; International Collaboration on Endocarditis Investigators.

Am Heart J. 2005 Nov;150(5):1086-91.

PMID:
16291003
31.

Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database.

Miro JM, Anguera I, Cabell CH, Chen AY, Stafford JA, Corey GR, Olaison L, Eykyn S, Hoen B, Abrutyn E, Raoult D, Bayer A, Fowler VG Jr; International Collaboration on Endocarditis Merged Database Study Group.

Clin Infect Dis. 2005 Aug 15;41(4):507-14. Epub 2005 Jul 6. Erratum in: Clin Infect Dis. 2005 Oct1;41(7):1075-77.

PMID:
16028160
32.

Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase.

Sammond DM, Nailor KE, Veal JM, Nolte RT, Wang L, Knick VB, Rudolph SK, Truesdale AT, Nartey EN, Stafford JA, Kumar R, Cheung M.

Bioorg Med Chem Lett. 2005 Aug 1;15(15):3519-23.

PMID:
15990302
33.

Surgeons' economic profiles: can we get the "right" answers?

Eisenstein EL, Bethea CF, Muhlbaier LH, Davidian M, Peterson ED, Stafford JA, Mark DB.

J Med Syst. 2005 Apr;29(2):111-24.

PMID:
15931798
34.

Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.

Harris PA, Cheung M, Hunter RN 3rd, Brown ML, Veal JM, Nolte RT, Wang L, Liu W, Crosby RM, Johnson JH, Epperly AH, Kumar R, Luttrell DK, Stafford JA.

J Med Chem. 2005 Mar 10;48(5):1610-9.

PMID:
15743202
35.

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models.

Dev IK, Dornsife RE, Hopper TM, Onori JA, Miller CG, Harrington LE, Dold KM, Mullin RJ, Johnson JH, Crosby RM, Truesdale AT, Epperly AH, Hinkle KW, Cheung M, Stafford JA, Luttrell DK, Kumar R.

Br J Cancer. 2004 Oct 4;91(7):1391-8.

36.

Impact of managed care on the treatment, costs, and outcomes of fee-for-service Medicare patients with acute myocardial infarction.

Bundorf MK, Schulman KA, Stafford JA, Gaskin D, Jollis JG, Escarce JJ.

Health Serv Res. 2004 Feb;39(1):131-52.

37.

A rare case of breast carcinoma co-existing with axillary mantle cell lymphoma.

Dutta Roy S, Stafford JA, Scally J, Selvachandran SN.

World J Surg Oncol. 2003 Dec 9;1(1):27.

38.

Efficient and regioselective synthesis of 2-alkyl-2H-indazoles.

Cheung M, Boloor A, Stafford JA.

J Org Chem. 2003 May 16;68(10):4093-5.

PMID:
12737599
39.

Relating the structure, activity, and physical properties of ultrashort-acting benzodiazepine receptor agonists.

Pacofsky GJ, Stafford JA, Cox RF, Cowan JR, Dorsey GF Jr, Gonzales SS, Kaldor I, Koszalka GW, Lovell GG, McIntyre MS, Tidwell JH, Todd D, Whitesell G, Wiard RP, Feldman PL.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3219-22.

PMID:
12372538
40.

Identification and structure-activity studies of novel ultrashort-acting benzodiazepine receptor agonists.

Stafford JA, Pacofsky GJ, Cox RF, Cowan JR, Dorsey GF Jr, Gonzales SS, Jung DK, Koszalka GW, McIntyre MS, Tidwell JH, Wiard RP, Feldman PL.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3215-8.

PMID:
12372537
41.

Post-myocardial infarction risk stratification in elderly patients.

Alexander KP, Galanos AN, Jollis JG, Stafford JA, Peterson ED.

Am Heart J. 2001 Jul;142(1):37-42.

PMID:
11431654
42.

Dual inhibition of human type 4 phosphodiesterase isostates by (R, R)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrrolidinecarboxylate.

Tian G, Rocque WJ, Wiseman JS, Thompson IZ, Holmes WD, Domanico PL, Stafford JA, Feldman PL, Luther MA.

Biochemistry. 1998 May 12;37(19):6894-904.

PMID:
9578576
43.

Relationship between physician and hospital coronary angioplasty volume and outcome in elderly patients.

Jollis JG, Peterson ED, Nelson CL, Stafford JA, DeLong ER, Muhlbaier LH, Mark DB.

Circulation. 1997 Jun 3;95(11):2485-91.

PMID:
9184578
44.

Introduction of a conformational switching element on a pyrrolidine ring. Synthesis and evaluation of (R*,R*)-(+/-)-methyl 3-acetyl-4-[3- (cyclopentyloxy)-4-methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate, a potent and selective inhibitor of cAMP-specific phosphodiesterase.

Stafford JA, Veal JM, Feldman PL, Valvano NL, Baer PG, Brackeen MF, Brawley ES, Connolly KM, Domanico PL, Han B, et al.

J Med Chem. 1995 Dec 22;38(26):4972-5. No abstract available.

PMID:
8544172
45.

Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase.

Brackeen MF, Cowan DJ, Stafford JA, Schoenen FJ, Veal JM, Domanico PL, Rose D, Strickland AB, Verghese M, Feldman PL.

J Med Chem. 1995 Nov 24;38(24):4848-54.

PMID:
7490734
46.

Phosphodiesterase type IV inhibition. Structure-activity relationships of 1,3-disubstituted pyrrolidines.

Feldman PL, Brackeen MF, Cowan DJ, Marron BE, Schoenen FJ, Stafford JA, Suh EM, Domanico PL, Rose D, Leesnitzer MA, et al.

J Med Chem. 1995 Apr 28;38(9):1505-10.

PMID:
7739009
47.

Comments on the asthma protocol.

Jones HD, Stafford JA.

J Am Coll Health. 1995 Mar;43(5):231. No abstract available.

PMID:
7499639
48.

Type II hyperprolinaemia in a pedigree of Irish travellers (nomads).

Flynn MP, Martin MC, Moore PT, Stafford JA, Fleming GA, Phang JM.

Arch Dis Child. 1989 Dec;64(12):1699-707.

49.

Alzheimer's disease: a study of epidemiological aspects.

Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T.

Ann Neurol. 1984 Apr;15(4):335-41.

PMID:
6742780
50.

Patient self-sufficiency: re-organisation of a diabetes clinic.

Beaven DW, Helm A, Stafford JA, Hunter AD.

N Z Med J. 1978 Sep 27;88(620):250-3. No abstract available.

PMID:
281624

Supplemental Content

Loading ...
Support Center